On November 3, 2023 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported a poster presentation on ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, at the 2023 SITC (Free SITC Whitepaper) (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) Annual Meeting, being held in San Diego November 1-5, 2023 (Press release, Alligator Bioscience, NOV 3, 2023, View Source [SID1234636874]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation, entitled "Combination treatment with ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro", outlines the use of CEACAM5 expressing tumor models to study the anti-tumor efficacy of ATOR-4066 and to analyze induction of immunological memory in vivo.
The presentation highlights that:
ATOR-4066 has a superior anti-tumor effect compared to a CD40 monospecific antibody
ATOR-4066 activation of CD40 expressing cells is CEACAM5-conditional with no activation in absence of CEACAM5 indicating a potential for a wide therapeutic window
ATOR-4066 is well positioned, with distinct advantages compared to other CD40 or CEACAM5 targeting therapies, such as strong anti-tumor effect in vivo also in larger tumors with heterogenous CEACAM5 expression
ATOR-4066 induces immunological memory in vivo and were able to clear homologous tumors upon re-challenge
Combining ATOR-4066 with anti-PD-1 in vitro in a mixed lymphocyte reaction assay[1] produces a clear synergistic effect observed on reactivation of exhausted T cells as measured by an increase in interferon gamma production
Using dissociated tumor cells from gastric cancer patients, ATOR-4066 induced activation of multiple tumor infiltrating immune cell populations (i.e. B cells, macrophages and T cells)
"To have this abstract accepted for presentation at this year’s prestigious SITC (Free SITC Whitepaper) annual meeting is a testament both to the promise of ATOR-4066 and to the diligent work of the Alligator scientific team," said Søren Bregenholt, CEO of Alligator Bioscience. "These data emphasize the potential of ATOR-4066 both as a monotherapy and as a combination partner for checkpoint inhibitors to further enhance the immune response in tumors and we continue to advance ATOR-4066 towards the clinic."
Poster Presentation Details
Abstract Number: 837
Title: Combination treatment with ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
Date/Time: Friday 3 November, 2023, 9.00 am – 7.00 pm PDT
Presenter: Ida Uddbäck, Scientist, Alligator Bioscience
Location: Exhibit Halls A and B1, San Diego Convention Center
[1] Mixed lymphocyte reaction (MLR) – a common method for assessing the cellular immune response.